All In MedTech

Device Trial Radar · NCT07805512

A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition

A Randomized, Evaluator-blinded, Parallel Group, No-treatment Controlled, Multicenter Study to Evaluate Effectiveness and Safety of Restylane® Shaype™ for Improvement of Jawline Definition in Chinese Subjects

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Sep 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Galderma R&DNot on our public-company list
Sponsor type
Industry
First posted
Sep 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, evaluator-blinded, parallel group, no-treatment controlled, multicenter study to evaluate effectiveness and the safety of Restylane Shaype for improvement of jawline definition in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve jawline definition. Study sites is approximately 6. A total of approximately 162 subjects will be randomized (2:1) to either treatment with Restylane Shaype Treatment Group (approximately 108subjects) or no-treatment Control Group (approximately 54 subjects).

Conditions

  • Jawline Definition

Interventions

  • Restylane ShaypeDevice

    Restylane Shaype is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Shaype has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder rate based on the Blind Evaluators' live assessment using the Galderma Jawline Scale(GJS) .Time frame: At 6 months after the last treatment for the Treatment group and at 6 months after baseline for the Control group.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Galderma Investigational Site #6340

    Beijing, Beijing Municipality, China · Not yet recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.